Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells
Shots:
- ExCellThera to receive up front- future contingent payments along with manufacturing and supply fees for the licensed molecules
- The collaboration validates the immense clinical and commercial potential of UM171 in additional fields of development
- The collaboration allows the ExcelThera to focus on clinical programs and commercial plans for ECT-001 cell therapy product along with cell expansion and rejuvenation platform & other pre/clinical areas of interest
Ref: Globe Newswire | Image: HRI Portal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com